SciSparc GERD acquisition boosts momentum as SPRC enters the device market, aiming to scale globally with innovative endoscopic technology.SciSparc GERD acquisition boosts momentum as SPRC enters the device market, aiming to scale globally with innovative endoscopic technology.

SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market

Scisparc Ltd. (Sprc) Stock: Jumps As Company Expands Into High-Growth Gerd Device Market

SPRC reported a notable stock rise today, with SciSparc trading at $3.0497 as of 10:40 AM EST. The strong increase highlights growing market confidence as SciSparc moves into the expanding GERD device segment. SPRC strengthens its position by advancing its strategy through a new intellectual property acquisition.

SciSparc Ltd. (Nasdaq: SPRC) Stock

SciSparc completed a binding term sheet with Xylo Technologies to obtain patents, trademarks and medical device rights. This action allows SciSparc to pursue commercialization of the MUSE endoscopic system, which supports minimally invasive GERD treatment. SciSparc aims to scale its reach by forming regional distribution agreements across high-growth territories.

The recent stock momentum reflects rising expectations for SciSparc as it diversifies beyond clinical-stage pharmaceutical activity. SPRC looks to build revenue streams through new medical technologies, reinforcing growth ambitions. SciSparc positions itself to capture value in a market expected to expand gradually.

Expansion Through Strategic Technology Acquisition

SPRC  plans to issue ordinary shares representing 19.99% of its capital to Xylo upon closing. The company may also opt to issue pre-funded warrants, providing flexibility during the transaction. The assets obtained include full ownership of the MUSE system and related intellectual property.

SciSparc expects to replicate Xylo’s prior commercialization structure to reach major medical markets. In 2019, Xylo secured $3 million upfront from a China licensing agreement, and SciSparc now seeks similar partnerships abroad. SciSparc targets North America, Europe and Latin America, where demand continues to rise.

The MUSE™ system is designed for transoral fundoplication, enabling GERD symptom relief through a non-surgical method. SciSparc anticipates increased adoption due to growing preference for minimally invasive procedures. This technology aligns with long-term healthcare trends focused on efficiency and patient recovery.

Market Outlook and Industry Context

According to industry research, the global GERD device market reached $2.5 billion in 2024. It is projected to reach $3.03 billion by 2030 at a CAGR of 3.24% from 2025. Consequently, SciSparc aligns with a sector demonstrating stable demand and gradual growth.

SciSparc’s expansion comes amid broader healthcare innovations targeting chronic digestive conditions. The company supports continued development through its majority-owned subsidiary, NeuroThera Labs Inc. This move signals SciSparc’s intent to extend beyond pharmaceuticals into high-value medical equipment.

SciSparc remains subject to completion of definitive agreements before finalizing the acquisition. The company maintains confidence in closing terms without regulatory complications. In the meantime, SciSparc continues advancing toward commercial readiness while capitalizing on current momentum.

Stock Performance and Strategic Position

SciSparc stock stabilized around $3.05 following initial volatility during market open. The trading surge indicates stronger recognition of the company’s new strategic direction. SPRC reinforces long-term positioning through technological expansion and wider geographic outreach.

SciSparc develops pharmaceutical candidates and now broadens ambitions within high-potential medical device markets. Its latest acquisition effort supports diversification and revenue acceleration. SPRC demonstrates proactive steps to strengthen competitiveness and market presence.

SciSparc plans further updates as negotiations progress and commercialization strategies unfold. The company remains focused on execution while maintaining regulatory compliance. SPRC moves forward with momentum as it transitions into the GERD device industry.

This article was originally published as SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market on Crypto Breaking News – your trusted source for crypto news, Bitcoin news, and blockchain updates.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin Reaffirms Original 2014 Ethereum Vision With Modern Web3 Technology Stack

Vitalik Buterin Reaffirms Original 2014 Ethereum Vision With Modern Web3 Technology Stack

TLDR: Ethereum proof-of-stake transition and ZK-EVM scaling solutions effectively realize the 2014 sharding vision. Waku evolved from Whisper to power decentralized
Share
Blockonomi2026/01/14 17:17
CME Group to Launch Solana and XRP Futures Options

CME Group to Launch Solana and XRP Futures Options

The post CME Group to Launch Solana and XRP Futures Options appeared on BitcoinEthereumNews.com. An announcement was made by CME Group, the largest derivatives exchanger worldwide, revealed that it would introduce options for Solana and XRP futures. It is the latest addition to CME crypto derivatives as institutions and retail investors increase their demand for Solana and XRP. CME Expands Crypto Offerings With Solana and XRP Options Launch According to a press release, the launch is scheduled for October 13, 2025, pending regulatory approval. The new products will allow traders to access options on Solana, Micro Solana, XRP, and Micro XRP futures. Expiries will be offered on business days on a monthly, and quarterly basis to provide more flexibility to market players. CME Group said the contracts are designed to meet demand from institutions, hedge funds, and active retail traders. According to Giovanni Vicioso, the launch reflects high liquidity in Solana and XRP futures. Vicioso is the Global Head of Cryptocurrency Products for the CME Group. He noted that the new contracts will provide additional tools for risk management and exposure strategies. Recently, CME XRP futures registered record open interest amid ETF approval optimism, reinforcing confidence in contract demand. Cumberland, one of the leading liquidity providers, welcomed the development and said it highlights the shift beyond Bitcoin and Ethereum. FalconX, another trading firm, added that rising digital asset treasuries are increasing the need for hedging tools on alternative tokens like Solana and XRP. High Record Trading Volumes Demand Solana and XRP Futures Solana futures and XRP continue to gain popularity since their launch earlier this year. According to CME official records, many have bought and sold more than 540,000 Solana futures contracts since March. A value that amounts to over $22 billion dollars. Solana contracts hit a record 9,000 contracts in August, worth $437 million. Open interest also set a record at 12,500 contracts.…
Share
BitcoinEthereumNews2025/09/18 01:39
U.S. politician makes super suspicious war stock trade

U.S. politician makes super suspicious war stock trade

The post U.S. politician makes super suspicious war stock trade appeared on BitcoinEthereumNews.com. Representative Gilbert Cisneros of California drew much attention
Share
BitcoinEthereumNews2026/01/14 17:27